Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NOW Foods ginseng recall

This article was originally published in The Tan Sheet

Executive Summary

NOW Foods has voluntarily recalled all lots of American Ginseng and placed "all American Ginseng product at its facility on hold" following FDA test results showing presence of quintozene and other fungicides in one lot of the product, firm announces Nov. 16. NOW also has "extended testing to all ginseng products beyond the one lot identified by FDA." The Bloomingale, Ill.-based firm says it responded to an Oct. 21 warning letter by detailing steps already taken to address the problem, including a "more extensive" product recall than the agency requested, and "increasing NOW's already impressive testing program to match the FDA's more sensitive testing procedures"...

You may also be interested in...

FDA Seizes Contaminated Ginseng From New Jersey Firm

FDA is issuing a national warning to consumers who may have used supplements containing fungicide-contaminated ginseng from Livingston, N.J.-based supplier FCC Products

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts